Targeted regulatory T cell activation by site-specific PEGylated interleukin-2 mitigates autoimmune inflammation
{{output}}
Dysregulation of immune homeostasis accompanied by regulatory T cell (Treg) dysfunction is a hallmark of various autoimmune and inflammatory diseases. While low-dose interleukin-2 (IL-2) treatment can enhance Treg levels and alleviate disease symptoms, its sho... ...
